Alcon Research
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Alcon Research sits in the top decile of US sponsors by registered trial count (#124 of 15,742 sponsors by registered trial count).
Alcon Research: 275 sponsored US clinical trials, 5 recruiting.
Alcon Research sponsors 275 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 248 completed. 87 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cataract, with 12 trials.
Top-decile sponsor footprint
Alcon Research ranks in the top decile of sponsors by registered trial count (#124 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
248 of 266 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
275 total, page 1 of 6
Clareon TruPlus Study
NCT07502456
Feasibility Study of an Accommodating IOL Design
NCT07147192
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
NCT07161635
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05769153
Hydrus® Microstent New Enrollment Post-Approval Study
NCT04553523
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
NCT07082816
Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix
NCT05796453
Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults
NCT07531043
An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults
NCT07578363
Evaluation of Delefilcon A Contact Lenses
NCT06884202
Visual Performance With Clareon® Vivity® Intraocular Lenses (IOLs)
NCT06784063
A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes
NCT06660290
DAILIES TOTAL1® Soft Contact Lenses - Post-Market Clinical Follow-up Study
NCT06483113
Post-market Clinical Follow-up Study of Alcon TOTAL30® Contact Lenses (Lehfilcon A)
NCT06408649
Evaluation of Reflex Tear Production
NCT06565624
A Study Designed to Evaluate Tear Production
NCT06544707
A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
NCT06544694
An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult Populations
NCT06538662
Study of Safety and Performance of a Novel Ocular Lubricant in Subjects With Dry Eye Disease
NCT06444516
Next Generation Rocklatan
NCT06441643
Post-market Clinical Follow-up Study of Alcon PRECISION1™ Spherical and PRECISION1™ for Astigmatism Soft Contact Lenses
NCT06462456
A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness
NCT06444529
Clinical Performance Evaluation of Two Frequent Replacement Silicone Hydrogel Multifocal Toric Contact Lenses
NCT06461455
Clinical Performance of Two Frequent Replacement Silicone Hydrogel Multifocal Contact Lenses
NCT06469242
Clareon PanOptix Pro vs. Clareon PanOptix - Study B
NCT06401551
Clareon PanOptix Pro vs. Clareon PanOptix - Study A
NCT06400745
Comparison of Clinical Performance of Two Monthly Replacement Toric Soft Contact Lenses
NCT06165627
Next Generation Cataract Surgery Study
NCT06071104
EX-PRESS® P-50 and EX-PRESS® P-200
NCT06119178
Clinical Assessment of a Daily Disposable Soft Silicone Hydrogel Contact Lens
NCT06044948
Air Optix® Night and Day® Aqua Continuous Wear
NCT05992675
Air Optix® Night and Day® Aqua Daily Wear
NCT05976750
Air Optix® Night and Day® Aqua Therapeutic Wear
NCT05956535
A Real-World Evidence (RWE) Long-Term Follow-Up Study to Assess Outcomes of Alcon Monofocal Intraocular Lenses
NCT05799950
Clareon IOL Retrospective Data Collection
NCT05796674
Clinical Performance Evaluation of Two Frequent Replacement Silicone Hydrogel Toric Contact Lenses
NCT05959200
Air Optix Plus HydraGlyde Multifocal Daily/Extended Wear Contact Lenses
NCT05886894
Air Optix Extended Wear Contact Lenses
NCT05886881
Air Optix Daily Wear Contact Lenses
NCT05827224
AONDA Therapeutic Indication Study I
NCT05891106
Assessing the Clinical Performance of Two Frequent Replacement Silicone Hydrogel Multifocal Toric Contact Lenses
NCT05886907
Clinical Performance Assessment of Two Silicone Hydrogel Daily Disposable Contact Lenses
NCT05725317
Evaluation of Clareon Vivity/Vivity Toric
NCT05852470
The Clinical Performance of Two Reusable Silicone Hydrogel Contact Lenses
NCT05766787
Air Optix Night and Day Aqua (AONDA) Retrospective Study 1
NCT05790928
Clinical Evaluation of a Manufacturing Process for a Frequent Replacement Silicone Hydrogel Multifocal Contact Lens
NCT05765227
Assessing the Clinical Performance of Two Frequent Replacement Silicone Hydrogel Multifocal Contact Lenses
NCT05702541
Clareon Toric vs Eyhance Toric
NCT05481125
Clinical Comparison of Two Daily Disposable Toric Soft Contact Lenses
NCT05483127
Clinical Performance of Two Reusable Silicone Hydrogel Contact Lenses
NCT05431478
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 23 |
| Phase 3 | 47 |
| Phase 4 | 40 |
Therapeutic Areas
Where Alcon Research enrollment is open (later-stage tilt)
5 recruiting of 275 indexed (2% open); 248 completed (90%).
Phase mix: 87 late (III/IV) vs 28 early (I/II) (later-stage heavy).
Top condition: Cataract (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Alcon Research: open-pipeline peers nationwide
Peers matched on 275 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Alcon Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 275 trials (± recruiting share)
- Boston Scientific Corporation · 280 trials · 8% recruiting
- Regeneron Pharmaceuticals · 280 trials · 22% recruiting
- SWOG Cancer Research Network · 270 trials · 10% recruiting
- Novartis · 265 trials · 0% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · 2% recruiting · 55 trials
- Lexicon Pharmaceuticals · 2% recruiting · 56 trials
- Société des Produits Nestlé (SPN) · 2% recruiting · 53 trials
- Eisai · 2% recruiting · 287 trials
Related
What to do with this Alcon Research page
275 registered trials is a research-attention snapshot, not an endorsement of Alcon Research or any single study.
- 5 of Alcon Research's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cataract is the condition Alcon Research studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cataract trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Alcon Research pipeline card: 275 registered trials from official public datasets.Report a data error.